Infection
Ibrexafungerp citrate by Scynexis for Fungal Infections: Likelihood of Approval
Nov
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ibrexafungerp citrate overview
Ibrexafungerp citrate (Brexafemme) is a semi-synthetic triterpenoid derivative of the natural product enfumafungin with potential anti-fungal activity. It is formulated as film coated tablets for oral route of administration. Brexafemme is indicated for the treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (VVC).
Ibrexafungerp citrate (SCY-078) is under development for the treatment of invasive pulmonary aspergillosis, fungal infections, candidiasis (including systemic and invasive), invasive aspergillosis, pneumocystis infections, recurrent vulvovaginal candidiasis, coccidioidomycosis, histoplasmosis, blastomycosis and aspergillosis. It is administered through oral and intravenous route. The drug candidate is a semi-synthetic triterpenoid derivative of the natural product enfumafungin-a structurally distinct class of glucan synthase inhibitors. It acts by targeting beta 1,3-D-glucan synthase.
Scynexis overview
Scynexis is a pharmaceutical company that discovers, develops and commercializes novel anti-infective for multiple serious fungal infections. The company offers products such as ibrexafungerp tablets for the treatment of vulvovaginal candidiasis, invasive candidiasis, invasive aspergillosis and refractory invasive fungal infections. Scynexis carries out clinical trials for its pipeline product in patients with invasive pulmonary aspergillosis, intolerant fungal diseases and candidiasis among others. The company operates in the US. Scynexis is headquartered in Jersey City, New Jersey, the US.
For a complete picture of Ibrexafungerp citrate’s drug-specific PTSR and LoA scores, buy the report here.
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
